Thomas Schulze
Fondateur chez FundaMental Pharma GmbH
Profil
Thomas Schulze is the founder of FundaMental Pharma GmbH, a company founded in 2016, where he currently holds the title of Non-Executive Director.
He previously held the position of Chief Executive Officer at Avontec GmbH from 2009 to 2010.
Dr. Schulze also worked at Bayer AG as a Principal and at november AG as Chief Operating Officer.
Additionally, he held the position of Principal at Bayer Yakuhin Ltd.
Dr. Schulze obtained a doctorate degree from Freie Universität Berlin.
Postes actifs de Thomas Schulze
| Sociétés | Poste | Début |
|---|---|---|
FundaMental Pharma GmbH
 FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | Fondateur | 01/01/2016 |
Anciens postes connus de Thomas Schulze
| Sociétés | Poste | Fin |
|---|---|---|
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | President | 19/04/2010 |
Bayer Yakuhin Ltd.
 Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan. | Corporate Officer/Principal | - |
| BAYER AG | Corporate Officer/Principal | - |
november AG
 november AG Financial ConglomeratesFinance November AG is a holding company, which engages in the founding, acquisition, development, and management of companies. Its activities focus on the fields of medical, environmental, and biotechnology. It also supports the business development of its subsidiary companies and investments. The company was founded on November 26, 1996 and is headquartered in Cologne, Germany. | Directeur des opérations | - |
Formation de Thomas Schulze
| Freie Universität Berlin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BAYER AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
november AG
november AG Financial ConglomeratesFinance November AG is a holding company, which engages in the founding, acquisition, development, and management of companies. Its activities focus on the fields of medical, environmental, and biotechnology. It also supports the business development of its subsidiary companies and investments. The company was founded on November 26, 1996 and is headquartered in Cologne, Germany. | Finance |
Bayer Yakuhin Ltd.
Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan. | Health Technology |
FundaMental Pharma GmbH
FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | Health Technology |
